logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Unveiled Good News About Prohost Picked Biotech Stocks

 The News Prohost Was Waiting for to Post Its Special Letter Prohost has one eye on the development-stage biotech and biopharmaceutical companies' scientific fundamentals and accomplishments as well as the financial results on the revenue-generating firms. Prohost has the second...

Read More

August 8, 2019

0

Spark Therapeutics: A usual reaction to SPK-8011 results should have been a celebration

When an investigational gene therapy gets excellent results, the usual reaction towards the developing firm is a celebration . This is especially true when the developing firm is Spark Therapeutics (ONCE) , which has already validated its gene therapy approach...

Read More

August 8, 2018

0

Nektar's Story Has Nothing to Do with the Efficacy Or the Value of NKTR-214

Nektar Therapeutics Story Everything was going well with Nektar Therapeutics ( NKTR ) stock during the Conference call regarding the firm’s Q2 financial results. (See the firm's press release under our Impacting News column). Following the Conference call the company...

Read More

August 9, 2019

0

Exelixis' Good News. Prohost Comprehensive Essay with Informative Real Stories About Biotech Stocks

Coming Soon at Prohost Biotech We have stories to tell about our picked stocks which we believe could deepen the Prohost Biotech readers’ understanding of our strategy regarding the evaluation of the biotech companies. Our strategy has made it possible...

Read More

January 7, 2020

0

Why the Recent Data from the Trial of Moderna's mRNA Vaccine is Important and Significant

Moderna's mRNA Vaccine Today could be one of the important early days as Moderna ( MRNA ) succeeded in cementing proof of concept for the validity of its messenger RNA ( mRNA ) as a vaccine. Moderna announced yesterday positive...

Read More

January 10, 2020

0

Regeneron: Successful Cure for Ebola-Infected People. Read Also: The Midday Outperforming Biotech Stocks

Regeneron Product REGN-EB3 Saving Lives Regeneron ( REGN )   announced that an independent monitoring board ended its investigational product REGN-EB3  trial after reviewing interim mortality data from 499 patients. REGN-EB3 was found superior to rival therapy from Mapp Biopharmaceuticals...

Read More

August 13, 2019

0

The XBiotech Interesting News That Rallied Its Stock

XBiotech XBiotech ( XBIT ), headquartered in Austin, Texas, develops innovative proprietary manufacturing technology that reduces the cost and complexity of biological drug production. XBiotech  is dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies. The firm is currently advancing...

Read More

January 14, 2020

0

Why Portola couldn’t flex its muscles or use them yet

All the buying and selling of Portola (PTLA)  will not make any sense to us until the firm fulfills its obligations towards what is required by the authorities, by health care and by private third-party payers.  So, in the reporting...

Read More

August 9, 2018

0

Nektar Is Still a Favorite

Nektar in the NEWS T he FDA's Anesthetic and Analgesic Advisory Committee ( AADPAC ) and Drug Safety and Risk Management Advisory Committee ( DSaRM ) unanimously voted no regarding the approval of Nektar Pharmaceuticals’ ( NKTR ) New Drug Application (...

Read More

January 15, 2020

0

Regeneron: Two good news and a rebound on the road

The FDA Approves Regeneron’s Product EyLea® (aflibercept) sBLA in Wet Age-Related Macular Degeneration Regeneron (REGN) has two good news. The first is from one of its approved products, EYLEA ® announcing that the U.S. Food and Drug Administration(FDA) has approved a...

Read More

August 17, 2018

0

  • Previous
  • 1
  • 2
  • ...
  • 79
  • 80
  • 81
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy